Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease

Niu, Qiang; Wang, Zhongsu; Zhang, Yong; Wang, Jiangrong; Zhang, Pei; Wang, Cong; Yin, Xiangcui; Hou, Yinglong

doi:10.1177/1074248416663647

Cited by 41 publications

(35 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[4][5][6][7] However, in the cardiovascular field, most analyses have focused on the association of PPI comedication with adverse cerebrocardiovascular events. [7][8][9][10] A recent study showed that clopidogrel could increase the risk of bleeding when ad-ministered to patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). 11) Because PPIs significantly reduce the risk of gastrointestinal (GI) bleeding associated with antiplatelet therapy, they are often administered in combination with clopidogrel.…”

mentioning

confidence: 99%

Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel

Liu

Chen

et al. 2019

Int. Heart J.

View full text Add to dashboard Cite

Previous studies have provided established evidence on adverse outcomes of the coadministration of proton pump inhibitors (PPIs) and clopidogrel, whereas cerebro-cardiovascular outcomes of PPI use in the absence of clopidogrel therapy remain controversial. In this study, we aimed to assess the association between PPIs and cerebro-cardiovascular outcomes independent of clopidogrel. Systematic searches were conducted in the Cochrane Library, PubMed, and Embase databases for all relevant studies up to August 2018. Odds ratios (ORs) with its 95% confidence intervals (CIs) were abstracted and pooled using the random-effects model. A total of 14 observational studies (13 cohort studies and 1 case-control study) were identified. Compared with non-PPI users, PPI users experienced higher risks of stroke (

show abstract

mentioning

confidence: 99%

Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel

Liu

Chen

et al. 2019

Int. Heart J.

View full text Add to dashboard Cite

show abstract

“…Единственный ИПП, биодоступность которого не зависит от генетического полиморфизма CYP 2C19, -рабепразол, что обуславливает предсказуемость его кли-нического эффекта и хорошие результаты в эрадикации Helicobacter pylori [31], а также обеспечивает наимень-ший спектр лекарственных взаимодействий, что особен-но актуально у коморбидных пациентов при необходимо-сти приема других препаратов (клопидогрел, нестероид-ные противовоспалительные препараты, дигоксин, нифе-дипин, фенитоин, теофиллин и др.) [32][33][34][35][36][37][38].…”

Section: основными симптомами гэрб являются: изжога (жжение за грудинunclassified

Actual Aspects of Anti-Secretor Therapy of Gastroesophageal Reflux Disease

Трухан¹,

Гришечкина²

2017

Med. sov.

View full text Add to dashboard Cite

D.I. TRUKHAN, I.A. GRISHECHKINA, Omsk State Medical University ACTUAL ASPECTS OF ANTI-SECRETOR THERAPY OF GASTROESOPHAGEAL REFLUX DISEASEIn recent years, GERD has attracted increased attention, which is associated with a clear tendency to increase the incidence of the disease. Adequate treatment of GERD is necessary, as this disease worsens the quality of life of patients, and prolonged existence and progression of esophagitis can lead to the development of strictures, Barrett's esophagus and esophageal cancer. The main, basic link in the treatment of GERD is effective antisecretory therapy. Inhibitors of proton pump are currently the basis for the treatment of acid-dependent diseases. Although all PPIs are very effective, the antisecretory effect of various drugs of this class may differ in different patients. Pharmacokinetics and metabolism of rabeprazole significantly differ from those of other PPIs. The clearance of rabeprazole is largely non-enzymatic and depends little on the functioning of the cytochrome P450 (CYP) 2C19 system, which makes predictable the effect of rabeprazole and its safety for patients taking several drugs at the same time. A distinctive effect of rabeprazole is the activation of rabeprazole over a wide pH range.

show abstract

“…Вероятность развития больших сосудистых событий оказалась одинаковой у пациентов, получавших ИПП четырех классов: омепразол, лансопразол, эзомепразол и пантопразол. Однако у больных, получавших рабепразол, повышения риска больших сосудистых событий не отмечено (отношение шансов = 1,03; 95% ДИ: 0,55-1,95) [11]. Наиболее вероятное объяснение этому -минимально выраженное взаимодействие рабепразола с системой цитохрома.…”

Section: заболевания пищевода и желудкаunclassified

Use of Rabeprazol in practice of gastroenterologist

Шульпекова¹

2016

Med. sov.

View full text Add to dashboard Cite

Ингибиторы протонной помпы (ИПП)-класс препаратов с бесспорно высокой эффективностью и хорошим профилем безопасности. С учетом значительного распространения кислотозависимых заболеваний в современном мире ИПП применяются чрезвычайно широко; современная практика без них немыслима. Вместе с тем нельзя не признать, что эти препараты нередко назначаются в отсутствие обоснованных показаний, в неоправданно высоких дозах и в течение чрезмерно длительного времени. В работах последних лет клиницисты и фармацевты призывают ответственно относиться к применению ИПП, в особенности «off label»-вне официальных показаний; в таких случаях необходимо взвешенно обосновывать это в медицинской документации.

show abstract

Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease

Cited by 41 publications

References 41 publications

Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel

Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel

Actual Aspects of Anti-Secretor Therapy of Gastroesophageal Reflux Disease

Use of Rabeprazol in practice of gastroenterologist

Contact Info

Product

Resources

About